Literature DB >> 22675253

Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome.

Yan Ding1, Ming An Zhu, Zhi Xiao Wang, Jing Zhu, Jing Bo Feng, Dong Sheng Li.   

Abstract

BACKGROUND: Acute coronary syndromes (ACSs) are clinically cardiovascular events associated with dyslipidemia in common. Single nucleotide polymorphisms (SNPs) and haplotypes in the APOA1/C3/A5 gene cluster are associated with diabetes and familial combined hyperlipidaemia (FCH). Little is known about whether the polymorphisms in these genes affect lipid homeostasis in patients with ACSs. The present paper aimed to examine these associations with 4 SNPs in the APOA1 -75G > A, the APOC3 -455T > C, and APOA5 -1131T > C, c.553G > T variant to ACSs in Chinese Han.
METHODS: Chinese Han of 229 patients with ACSs and 254 unrelated controls were analyzed. Four SNPs in APOA1/C3/A5 cluster were genotyped and lipid was determined.
RESULTS: Our data show that minor allelic frequencies of APOC3 -455T > C, APOA5 -1131T > C, and c.553G > T polymorphisms in patients with ACSs were significantly higher than control group (P < 0.05). Furthermore, the 3 polymorphic sites were strongly of linkage disequilibrium, and minor alleles of 3 SNP sites had higher TG level than wild alleles (P < 0.05), APOC3 -455C and APOA5 c.553T allele carriers also had lower level of HDL-C.
CONCLUSIONS: The minor alleles of APOC3 -455T > C, APOA5 -1131T > C, and c.553G > T polymorphisms are closely associated with ACSs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22675253      PMCID: PMC3366243          DOI: 10.1155/2012/509420

Source DB:  PubMed          Journal:  J Biomed Biotechnol        ISSN: 1110-7243


1. Introduction

Acute coronary syndromes (ACSs), including unstable angina (UA) and acute myocardial infarction (AMI), are clinically cardiovascular events resulted from the rupture of atherosclerotic plaque, followed by inflammation associated with acute-phase response. Atherosclerosis, the major event leading to ACSs, is characterized by the events following accumulation of lipids and fibrous elements in coronary arteries, several risk factors such as genetic and environmental have been identified; most importantly levels of HDL, triglycerides, lipoprotein (a), diabetes mellitus, smoking, and hypertension [1, 2]. Meanwhile, dyslipidemia is common and associated with increased mortality rates in hospitalized patients with ACS [3]. Dyslipidemia often occurs in ACSs patients, however, the incidence of underlying mechanisms in this disease remain poorly understood. The Apolipoprotein A1-C3-A4-A5 gene cluster on chromosome 11q23 (Apo11q) is among the most well-characterized regions of the human genome with reference to their dynamic association with plasma lipids and lipoproteins [4]. The associated haplotypes constitute a highly informative genetic marker [5]. Extensive interactions both within and between the genetic variants within this cluster contribute to the quantitative variation in the blood lipid phenotypes [6]. The SNPs in the Apo11q region, particularly the −455T > C of the APOC3 gene [7], as well as −1131C > T promoter SNP and S19W SNP in exon 2 of the APOA5 gene [8, 9], have been shown to independently and in tandem, regulate plasma TG levels [10]. The two promoter SNPs, −75G > A and +83C > T in the APOA1 gene, have shown strong association with HDL-C and ApoA1 levels [11]. The aim of this study was to analyze the relationship of SNPs in the APOA1/C3/A4/A5 cluster with ACSs in Chinese Han.

2. Materials and Methods

2.1. Study Population

The patient group consisted of 229 unrelated patients ranging in age from 40 to 75 years old (mean, 59 years old); all had symptoms of ischemia that were verified by electrocardiography [ST segment depression (≥0.1 mm), T-wave inversion (≥0.1 mm)], or increased levels of biochemical markers (creatine kinase myoglobin binding isoenzyme [CK-MB], >6.6 μg/L or troponin I [TnI], >0.3 μg/L [0.3 ng/mL]). The diagnosis of ACS was established on the basis of current definitions [12]. Control group consisted of 254 unrelated healthy people all in mean age at 59 years old. The inclusion criteria for the control group were without a clinical history of CVD, cardiovascular risk factorshistory, or diagnosis of atherosclerosis, vascular disease, chronic heart failure, and arrhythmias, diabetes mellitus, or cancer, and those with a normal electrocardiograph and normal blood chemistry values were included. After an overnight fast for a minimum of 12 h, blood was drawn into EDTA-containing tubes for analysis of lipid profiles. Plasma was prepared by immediate centrifugation (1,800 g, 15 min, 4°C), and samples were stored at −80°C until further analyses. Serum total cholesterol, low-density lipoprotein (LDL) cholesterol, HDL cholesterol, and triglyceride (TG) concentrations were measured enzymatically on a Hitachi 7450 Analyzer (Hitachi, Japan) using Roche reagents.

2.2. Genetic Analysis

DNA was isolated from peripheral blood leukocytes by a standard salting out method. Details of PCR primers, annealing conditions, and restriction enzyme digestion were according to others [13-15]. In short, the genomic regions encompassing the polymorphic sites were PCR amplified using site-specific primers, restriction digested with appropriate restriction enzymes (Msp I restriction enzyme for APOA1 −75G > A and APOA5 c.553G > T, BseG I for APOC3 −455T > C, Mse I for APOA5 −1131T > C), and the digests were resolved on 2% agarose gel for the APOA1 and the APOA5 SNPs, while the APOC3 genotypes were resolved by 6% polyacrylamide gel electrophoresis (PAGE).

2.3. Statistical Analysis

The statistical analyses were carried out with SPSS 14.0 software. All data are expressed as mean ± standard deviation (SD). Frequencies of the alleles were estimated by gene counting. Agreement of genotype frequencies with Hardy-Weinberg equilibrium expectations was tested using χ2 test. The clinical characteristics of study subjects were compared by unpaired Student's t-test. The lipid levels difference among every genotype were tested with ANCOVA. The χ2 test was used to compare the qualitative data. Logistic regression analysis models were used to evaluate the haplotypes as possible risk factors. To determine the extent of LD in our sample, standardized LD coefficients D′ was calculated for all pairs of polymorphisms.

3. Results

3.1. Characteristics of Controls and Patients

General characteristics of 229 ACS patients and 254 healthy controls are shown in Table 1. ACS patients showed higher systolic blood pressure, TG, total and LDL-cholesterol, and glucose but lower HDL-cholesterol levels than controls.
Table 1

General clinical information and blood fat concentration comparison of the two groups.

ACS group (n = 229)Control group P
(n = 254)
Gender (male/female)128/101137/117NS
Age (mean year)59.1 ± 9.459.3 ± 9.6NS
BMI (kg/m2)23.24 ± 3.2622.75 ± 2.97<0.01
SBP (mmHg)126.10 ± 12.43121.93 ± 3.10<0.01
DBP (mmHg)74.4 ± 4.674.8 ± 4.8NS
Total cholesterol (TC, mmol/L)5.04 ± 1.334.77 ± 1.07<0.01
Triglyceride (TG, mmol/L)2.02 ± 0.521.38 ± 0.39<0.01
HDL-C (mmol/L)1.03 ± 0.341.28 ± 0.31<0.01
LDL-C (mmol/L)3.87 ± 0.912.44 ± 0.68<0.01
Blood glucose (mmol/L)5.04 ± 1.334.77 ± 1.07<0.01

Systolic blood pressure and diastolic blood pressure. ACS: coronary artery disease; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein.

3.2. Allele Frequency and Linkage Disequilibrium

Genotype distributions for these polymorphisms were in Hardy-Weinberg equilibrium. As shown in Table 2, the minor allelic frequencies of −1131T > C and c. 553G > T polymorphisms of APOA5 in patients with ACS (41.3% and 9.8%) were significantly higher than those of the control subjects (31.1% and 4.9%, resp.). Frequency of C allele of APOC3 −455T > C in patients with ACS was also significantly higher than that of normal subjects (26.9% and 17.3%, resp.). However, this difference was not observed in that of APOA1 −75G > A (P > 0.05) (Table 2).
Table 2

Comparison of genotype frequencies and Hardy-Weinberg equilibrium test results of the four polymorphisms in the apolipoprotein A1/C3/A5 gene cluster between control and ACS group.

ACSControls P
(n = 229)(n = 254)
APOA1 −75G > AGG41% (94)42.5% (108)
GA41.5% (95)48.8% (124)0.012
AA17.5% (40)8.7% (22)
G61.8% (283)66.9% (340)
A39.2% (175)33.1% (168)0.096

APOC3 −455T > CTT20% (46)26.4% (67)
TC50% (115)53.9% (137)0.026
CC30% (68)19.7% (50)
T73.1% (207)82.7% (271)
C26.9% (251)17.3% (237)0.012

APOA5 −1131T > CTT38.9% (89)52% (132)
TC39.7% (91)33.9% (86)0.01
CC21.4% (49)14.1% (36)
T58.7% (269)68.9% (350)
C41.3% (189)31.1% (158)0.001

APOA5 c.553G > TGG81.2% (186)90.9% (231)
GT17.9% (41)8.3% (21)0.007
TT0.9% (2)0.8% (2)
G90.2% (413)95.1% (483)
T9.8% (45)4.9% (25)0.003
To determine the extent of LD in our study sample, standardized LD coefficients D′ was calculated for all pairs of polymorphisms. Table 3 shows the LD matrix generated using D′. As shown in Table 3, except for APOA1 −75G > A, the other 3 polymorphic sites were in strong linkage disequilibrium (D′ > 0.8).
Table 3

Standardized linkage disequilibrium coefficient (D′) among four APOA1/C3/A5.

APOC3APOA5APOA5
−455T > C−1131T > Cc.553G > T
APOA1 −75G > A0.190.200.05
APOC3 −455T > C 0.830.86
APOA5 −1131T > C 0.92

3.3. Lipid Level and Association Analysis

We found that APOC3 −455T > C, APOA5 c.553G > T, and −1131T > C SNPs were all significantly associated with lipid levels. Specifically, the minor allele's carrier of the three SNPs showed a significant higher triglyceride, and APOC3 −455C and APOA5 c.553T allele carriers also showed a significant lower HDL cholesterol level than subjects with wild genotypes (Table 4). No significant differences of triglycerides and HDL cholesterol levels genotypes were found in APOA1 −75G > A.
Table 4

Comparison of HDL-C and TG level of the four polymorphisms in the apolipoprotein A1/C3/A5 gene cluster of the study participants.

  TG(483)HDL-C(483)
Mean ± SD P Mean ± SD P
APOA1 −75G > AGG1.72 ± 0.37 NS1.19 ± 0.34 NS
GA + AA1.58 ± 0.341.17 ± 0.24

APOC3 −455T > CTT1.43 ± 0.34 <0.011.22 ± 0.36 <0.01
TC + CC2.06 ± 0.451.04 ± 0.30

APOA5 −1131T > CTT1.32 ± 0.38 <0.011.15 ± 0.43 NS
TC + CC2.09 ± 0.441.10 ± 0.38

APOA5 c.553G > TGG1.47 ± 0.32 <0.011.24 ± 0.41 <0.01
GT + TT2.02 ± 0.480.97 ± 0.31
Multiple logistic regression for best selection model in above genotypes after adjusting age, gender, and body mass index is shown in Table 5; we can see that except for APOA1 −75G > A, the minor allele of each of other three polymorphisms (APOC3 −455T > C, and the APOA5, −1131T > C and c.553G > T) were associated with ACS.
Table 5

Odds ratios of ACS and 95% confidence intervals (CI) in relation to the presence of different alleles of apolipoprotein gene after adjusting for age, gender, and BMI values.

VariableOdds ratio (95% CI) P
APOA1 −75G > A(AA and GA)/GG0.913 (0.6358–1.313)NS
APOC3 −455T > C(GG and GC)/CC2.043 (1.413–3.956)0.000
APOA5 −1131T > C(CC and CT)/TT3. 702 (2.185–5.445)0.001
APOA5 c.553G > T(TT and TG)/GG2.344 (1.477–4.290)0.001

4. Conclusion

In this study, the frequency of the APOA5 c.553T allele in ACS patient group was significantly higher than that of the controls. Compared with the participants with major alleles (APOA5 −1131TT and c.553GG), those homozygous for both SNPs (APOA5 −1131CC and c.553TT) had higher triglyceride concentrations (Table 4). Subjects homozygous for c.553TT also had higher HDL-C than those with c.553GG. All these data suggested the importance of APOA5 in the regulation of plasma triglyceride concentrations. Furthermore, pair wise linkage disequilibrium comparison performed in this study betweenAPOC3 and APOA5 demonstrated that they are linked (D′ < 0.8), suggesting cooperation mechanisms for the associations with plasma lipoproteins and related traits.

5. Discussion

ACSs are a multifactor disease in which a multitude of lifestyle and genetic factors contribute to the development and outcome of the disease [16]. Many papers show that apolipoprotein A1/C3/A4/A5 gene cluster is associated with premature coronary artery disease [17] and serum lipid levels [18-25]. Recent findings indicate that APOA5 could also influence cholesterol homeostasis and probably play a role in hypertriglyceridemia associated with diabetes and inflammation [20]. The frequency of APOC3 −455C allele in ACSs patients was significantly higher than that of normal subjects. This genetic variation was associated with variation in plasma concentrations of TG and HDL cholesterol in a manner consistent with many other reports from diverse populations [26, 27]. Specifically, we found that the C allele was associated with higher TG and lower HDL cholesterol; in addition, population studies have elucidated genetic association of APOC3 with HDL cholesterol levels [28]. These observations suggest that the functional APOC3 SNP mediates the widely replicated associations of hypertriglyceridemia and lower HDL cholesterol. In summary, we demonstrated that common variants of APOA1, APOC3, and APOA5 genes are associated with ACS and contribute to the variation in human plasma TG levels. Therefore, APOA5 variant was a significant predictor for high triglyceride/HDL risk and the APOA1/C3/A4/A5 haplotypes affected dyslipidemia appreciably among ethnic Chinese. Variations of these genes may be associated with the development of ACSs. They could be served as a useful genetic marker for diagnosis of ACSs.
  28 in total

1.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.

Authors:  Philippa J Talmud; Emma Hawe; Steve Martin; Michael Olivier; George J Miller; Edward M Rubin; Len A Pennacchio; Steve E Humphries
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

2.  Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change.

Authors:  Jaroslav A Hubacek; Romana Bohuslavova; Zdena Skodova; Jan Pitha; Dagmar Bobkova; Rudolf Poledne
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

3.  Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study.

Authors:  D Michael Hallman; Sathanur R Srinivasan; Wei Chen; Eric Boerwinkle; Gerald S Berenson
Journal:  Metabolism       Date:  2006-12       Impact factor: 8.694

4.  APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica.

Authors:  Edward A Ruiz-Narváez; Yadong Yang; Yukiko Nakanishi; Jill Kirchdorfer; Hannia Campos
Journal:  J Lipid Res       Date:  2005-09-28       Impact factor: 5.922

5.  Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster.

Authors:  Sara C Hamon; Sharon L R Kardia; Eric Boerwinkle; Kiang Liu; Kathy L E Klos; Andrew G Clark; Charles F Sing
Journal:  Hum Hered       Date:  2006-05-19       Impact factor: 0.444

Review 6.  Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?

Authors:  Heidelinde Jakel; Maxime Nowak; Audrey Helleboid-Chapman; Jamila Fruchart-Najib; Jean-Charles Fruchart
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

7.  Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol.

Authors:  M I Kamboh; C E Aston; C M Nestlerode; A E McAllister; R F Hamman
Journal:  Atherosclerosis       Date:  1996-12-20       Impact factor: 5.162

8.  Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes.

Authors:  Anders Mälarstig; Taavo Tenno; Nina Johnston; Bo Lagerqvist; Tomas Axelsson; Ann-Christine Syvänen; Lars Wallentin; Agneta Siegbahn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-10-20       Impact factor: 8.311

9.  Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes.

Authors:  Marilu Fiegenbaum; Fabiana Michelsen de Andrade; Mara H Hutz
Journal:  Clin Chim Acta       Date:  2007-02-15       Impact factor: 3.786

10.  Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons.

Authors:  Qian-fei Wang; Xin Liu; Jeff O'Connell; Ze Peng; Ronald M Krauss; David L Rainwater; John L VandeBerg; Edward M Rubin; Jan-Fang Cheng; Len A Pennacchio
Journal:  Hum Mol Genet       Date:  2004-03-25       Impact factor: 6.150

View more
  18 in total

1.  Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.

Authors:  Daniel B Larach; Marina Cuchel; Daniel J Rader
Journal:  Clin Lipidol       Date:  2013-12

2.  Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population.

Authors:  Min-Rui Li; Sheng-Hong Zhang; Kang Chao; Xian-Hua Liao; Jia-Yan Yao; Min-Hu Chen; Bi-Hui Zhong
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis.

Authors:  Jing-Zhan Zhang; Xiang Xie; Yi-Tong Ma; Ying-Ying Zheng; Yi-Ning Yang; Xiao-Mei Li; Zhen-Yan Fu; Chuan-Fang Dai; Ming-Ming Zhang; Guo-Ting Yin; Fen Liu; Bang-Dang Chen; Min-Tao Gai
Journal:  Aging Dis       Date:  2016-01-02       Impact factor: 6.745

4.  Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage.

Authors:  Yan Jiang; Junpeng Ma; Hao Li; Yi Liu; Chao You
Journal:  Lipids Health Dis       Date:  2015-05-22       Impact factor: 3.876

5.  Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population.

Authors:  FengHe Cui; KeZhong Li; YunFeng Li; XueWu Zhang; ChangShan An
Journal:  Lipids Health Dis       Date:  2014-11-08       Impact factor: 3.876

6.  Erratum: Question Marks Left Over a Quantitative Assessment of Apolipoprotein C3 Gene Polymorphisms.

Authors:  Philipp G Sand
Journal:  Aging Dis       Date:  2016-05-27       Impact factor: 6.745

Review 7.  Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review.

Authors:  Xiao-Lin Li; Jian-Qing Sui; Lin-Lin Lu; Nan-Nan Zhang; Xin Xu; Quan-Yong Dong; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2016-03-10       Impact factor: 3.876

8.  Positive Association between APOA5 rs662799 Polymorphism and Coronary Heart Disease: A Case-Control Study and Meta-Analysis.

Authors:  Huadan Ye; Annan Zhou; Qiangxiao Hong; Linlin Tang; Xuting Xu; Yanfei Xin; Danjie Jiang; Dongjun Dai; Yirun Li; Dao Wen Wang; Shiwei Duan
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

9.  Association of two common polymorphisms of apolipoprotein A5 gene with metabolic syndrome indicators in a North Iranian population, a cross-sectional study.

Authors:  Sohrab Halalkhor; Farzad Jalali; Karimollah Hajian Tilaki; Shahla Shojaei
Journal:  J Diabetes Metab Disord       Date:  2014-04-07

10.  Association of Apolipoprotein C3 Genetic Polymorphisms with the Risk of Ischemic Stroke in the Northern Chinese Han Population.

Authors:  Yanzhe Wang; Xiaoyu Yin; Lei Li; Shumin Deng; Zhiyi He
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.